Full-Time

Business Process Analyst

Cfso

Confirmed live in the last 24 hours

Penumbra Inc

Penumbra Inc

1,001-5,000 employees

Develops medical devices for vascular conditions

Compensation Overview

$82.4k - $133.9k/yr

Senior

Company Historically Provides H1B Sponsorship

Alameda, CA, USA

Hybrid

Hybrid position requiring some in-office presence.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
SAP Products
Word/Pages/Docs
Excel/Numbers/Sheets
Requirements
  • Bachelor's degree in business, IT, or related field with 5+ years of experience, or equivalent combination of education and experience
  • Experience with SAP
  • Detailed understanding of OTC process and transactional implications
  • Strong oral, written, and interpersonal communication skills
  • High degree of accuracy and attention to detail
  • Proficiency with MS Word, Excel, and PowerPoint
  • Excellent organizational skills with ability to prioritize assignments while handling various projects simultaneously
Responsibilities
  • Collaborate actively with business partners, including end users within CFSO, IT, Accounting, Sales Operations, and Quality to analyze and document business requirements and recommend, project manage, test and implement solutions
  • Effectively communicate and mediate an outcome
  • Project manage and effect change management, including planning, implementing and solidifying the changes
  • Improve and optimize current systems in the business
  • Work with end users to create compelling business case for new applications or functionality, including cost/benefit and risk/impact analysis
  • Collaborate closely with other teams and understand overlaps of teams and applications to troubleshoot/resolve issues
  • Work with end users as needed to develop and execute test plans to verify business systems and processes work as expected
  • Develop and recommend operational processes and/or process improvements focused on aligning with industry standards and best practices
  • Support production system incidents; troubleshoot and provide root cause analysis; participate in user acceptance testing (UAT) to ensure quality of changes
  • Ability to work independently, manage multiple projects simultaneously, and have excellent communication and collaboration skills
  • Adhere to the Company’s Quality Management System (QMS) as well as domestic and global quality system regulations, standards, and procedures
  • Understand relevant security, privacy and compliance principles and adhere to the regulations, standards, and procedures that are applicable to the Company
  • Ensure other members of the department follow the QMS, regulations, standards, and procedures
  • Perform other work-related duties as assigned
Desired Qualifications
  • Medical device, pharmaceutical, biotech, or other regulated industry experience desired
  • Experience with SAP, GHX and Salesforce is highly desirable

Penumbra Inc. specializes in creating medical devices for treating neurovascular and peripheral vascular conditions. Their products, such as the Penumbra System and Indigo System, are designed to assist healthcare professionals in addressing issues like stroke and other vascular diseases. These devices work by providing advanced tools for interventions in neurology and vascular surgery, allowing for effective treatment options. Unlike many competitors, Penumbra focuses on a specific range of specialized devices and emphasizes continuous research and development to enhance their offerings. The company's goal is to deliver high-quality medical solutions that meet the needs of healthcare providers and improve patient outcomes.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Alameda, California

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance of Ruby XL System enhances Penumbra's product portfolio.
  • Increased adoption of AI in medical imaging complements Penumbra's neurovascular devices.
  • Telemedicine growth offers new integration opportunities for Penumbra's devices.

What critics are saying

  • Increased competition may impact Penumbra's market share in neurovascular devices.
  • Don Kassing's retirement could create a temporary leadership gap.
  • Italian regulatory challenges may affect Penumbra's financial performance.

What makes Penumbra Inc unique

  • Penumbra offers a comprehensive range of neuro and peripheral vascular devices.
  • The company focuses on innovative solutions for stroke and neurovascular disease treatment.
  • Penumbra's global presence spans North America, Europe, Asia, and Australia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Parental Leave

Paid Vacation

Paid Sick Leave

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Medical Device Network
Jun 6th, 2025
Penumbra announces FDA clearance and launch of detachable embolisation coil

Penumbra has introduced Ruby XL System, the detachable embolisation coil, which has also received clearance from the US Food and Drug Administration (FDA).

BioSpace
Apr 29th, 2025
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference

ALAMEDA, Calif., April 29, 2025 /PRNewswire/ - Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025.

Neuro News International
Apr 24th, 2025
Penumbra announces Red 72 Silver Label product featuring company's latest engineering enhancements

Penumbra announces Red 72 Silver Label product featuring company's latest engineering enhancements.

PR Newswire
Apr 3rd, 2025
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release And Conference Call For April 23, 2025

ALAMEDA, Calif., April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. A press release with first quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.About PenumbraPenumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life

Penumbrainc
Mar 17th, 2025
Latest Data on Penumbra's CAVT Technology to Be Presented at SIR 2025: STRIDE, STRIKE-PE, and More

Latest data on Penumbra's CAVT technology to be presented at SIR 2025: STRIDE, STRIKE-PE, and more.